[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-567717-105":53,"doc-detail-567717-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","cytopoint-solution-for-injection-for-dogs-dosing-chart-atopic-dermatitis","CYTOPOINT Solution for Injection for Dogs - Dosing Chart - Atopic Dermatitis","","CYTOPOINT is a lokivetmab injection for dogs indicated for treating clinical manifestations of atopic dermatitis. The dosing chart provides monthly subcutaneous administration guidance based on bodyweight, including handling for dogs above 40 kg using multiple vials and gentle mixing before injection. Key precautions cover hypersensitivity risk, anti-drug antibody development, monitoring for infections, vaccine site separation, and refrigeration storage. Guidance also includes pregnancy and lactation limitations, overdose management, and legal classification POM-V.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":51,"@type":70,"position":76},"https://docshare.wps.com/template/general/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/cytopoint-solution-for-injection-for-dogs-dosing-chart-atopic-dermatitis/567717/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/cytopoint-solution-for-injection-for-dogs-dosing-chart-atopic-dermatitis/567717.png","ImageObject",442,249,{"name":88,"@type":89},"anakgang17","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-25","2026-10-13",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",7,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What is CYTOPOINT (lokivetmab) indicated for in dogs?","Question",{"text":109,"@type":110},"CYTOPOINT is indicated for treating the clinical manifestations of atopic dermatitis in dogs.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"How is CYTOPOINT administered and what is the dosing schedule?",{"text":114,"@type":110},"It is given by subcutaneous injection. Administer the entire 1 ml vial contents, with a recommended minimum dose of 1 mg/kg bodyweight once a month according to the dosing chart.",{"name":116,"@type":107,"acceptedAnswer":117},"What warnings are important regarding hypersensitivity and anti-drug antibodies?",{"text":118,"@type":110},"Do not use in cases of hypersensitivity to the active substance or excipients. Lokivetmab may induce transient or persistent anti-drug antibodies, and hypersensitivity reactions including anaphylaxis can occur rarely, especially after accidental self-injection.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},567717,1792097075,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":50,"category_name":51,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":73,"language":136,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":61,"update_tm":140,"read_time":9},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","CYTOPOINT® SOLUTION FOR INJECTION FOR DOGS  \nPRESENTATION  \nEach vial of 1 ml contains 10, 20, 30 or 40 mg Lokivetmab. Lokivetmab is a caninised monoclonal antibody expressed through recombinant techniques in Chinese hamster ovary (CHO) cells.  \nUSES  \nIndicated for the treatment of clinical manifestations of atopic dermatitis in dogs.  \nDOSAGE AND ADMINISTRATION  \nFor subcutaneous use. Avoid excessive shaking or foaming of the solution. Administer the entire contents (1 ml) of the vial.  \nDose according to the dosing chart below. For dogs above 40 kg, the contents of more than one vial are required toadminister in a single dose. In those cases, withdraw the appropriate content from each required vial into the same syringe. To allow for mixing of the solution, gently invert the syringe three or four times before administering. Dosage and treatment schedule:  \nThe recommended minimum dose is 1 mg/kg bodyweight, once a month. Dose according to the dosing chart below:  \n\n| Bodyweight (kg) of dog | Cytopoint strength (mg) to be administered |  |  |  |\n| --- | --- | --- | --- | --- |\n|  | 10 | 20 | 30 | 40 |\n| 3.0 – 10.0 | 1 vial |  |  |  |\n| 10.1 – 20.0 |  | 1 vial |  |  |\n| 20.1 – 30.0 |  |  | 1 vial |  |\n| 30.1 – 40.0 |  |  |  | 1 vial |\n| 40.1 – 50.0 | 1 vial |  |  | 1 vial |\n| 50.1 – 60.0 |  |  | 2 vials |  |\n| 60.1 – 70.0 |  |  | 1 vial | 1 vial |\n| 70.1 – 80.0 |  |  |  | 2 vials |\n\nCONTRA-INDICATIONS, WARNINGS, ETC  \nDo not use in cases of hypersensitivity to the active substance or to any of the excipients.  \nDo not use in dogs less than 3 kg bodyweight.  \nLokivetmab may induce transient or persistent anti-drug antibodies. The induction of such antibodies is uncommon and may have no effect (transient anti-drug antibodies) or may result in a noticeable decrease in efficacy (persistent anti-drug antibodies) in animals that responded to treatment previously.  \nIn cases of atopic dermatitis, it is recommended to investigate and treat complicating factors, such as bacterial, fungal or parasitic infections/infestations (e.g. flea and mange) .  \nIt is recommended to monitor dogs for bacterial infections associated with atopic dermatitis, especially during the first weeks of treatment.  \nIf no or limited response is observed within one month after initial dosing, an improvement in response maybe observed after administration of a second dose one month later. However, if the animal does not show a better response after the second dose, the veterinary surgeon should consider alternative treatments.  \nThe safety of the veterinary medicinal product has not been established during pregnancy and lactation; therefore its use is not recommended during pregnancy, lactation orin breeding animals.  \nNo drug interactions were observed in field studies where lokivetmab was administered concomitantly with veterinary medicinal products such as endo-andectoparasiticides, antimicrobials, anti-inflammatories and vaccines.  \nIf a vaccine(s) is to be administered at the same time as treatment with lokivetmab, the vaccine(s) should be administered at a different site to that of lokivetmab administration.  \nDo not mix with any other veterinary medicinal product. Hypersensitivity reactions (anaphylaxis, facial oedema, urticaria) may occur in rare cases. In such cases appropriate treatment should be administered immediately. The frequency of adverse reactions is defined using the following convention:  \n− very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)  \n− common (more than 1 but less than 10 animals in 100 animals)  \n− uncommon (more than 1 but less than 10 animals in 1,000 animals)  \n− rare (more than 1 but less than 10 animals in 10,000 animals)  \n− very rare (less than 1 animal in 10,000 animals, including isolated reports) .  \nNo adverse reactions other than those mentioned above were observed in laboratory overdose studies. In case of adverse clinical signs after an overdose the dog should be t","cbCairV7Yua4n8B1","https://ap.wps.com/l/cbCairV7Yua4n8B1","pdf",52867,"English","# Uses\n# Dosage and Administration\n## Dosing chart by bodyweight\n# Contra-indications, Warnings, Etc.\n# Pharmaceutical Precautions\n# Legal Category\n# Packaging Quantities\n# Further Information","[{\"question\":\"What is CYTOPOINT (lokivetmab) indicated for in dogs?\",\"answer\":\"CYTOPOINT is indicated for treating the clinical manifestations of atopic dermatitis in dogs.\"},{\"question\":\"How is CYTOPOINT administered and what is the dosing schedule?\",\"answer\":\"It is given by subcutaneous injection. Administer the entire 1 ml vial contents, with a recommended minimum dose of 1 mg/kg bodyweight once a month according to the dosing chart.\"},{\"question\":\"What warnings are important regarding hypersensitivity and anti-drug antibodies?\",\"answer\":\"Do not use in cases of hypersensitivity to the active substance or excipients. Lokivetmab may induce transient or persistent anti-drug antibodies, and hypersensitivity reactions including anaphylaxis can occur rarely, especially after accidental self-injection.\"}]","CYTOPOINT Solution for Injection for Dogs - Dosing Chart - Atopic Dermatitis | PDF",1791867631]